Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response [CR] or partial response [PR]) to platinum-based chemotherapy.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||01/06/2018|
|Rapid review completed||21/06/2018|
|Rapid Review outcome||A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care|
|Full pharmacoeconomic assessment commissioned by HSE||27/06/2018|